The European Medicines Agency is seeking greater cooperation with health-technology bodies that regulate the cost-efficacy of new drugs in European Union countries, EMA Executive Director Guido Rasi told audience at a Bloomberg Industries conference in London. The regulatory process should be condensed by collaborating with groups like the U.K.'s National Institute for Health and Care Excellence, instead of working separately, Rasi said. "We can do the development in sequence or in parallel, which makes a huge difference in time, but also a difference in outcome," Rasi said.

Full Story:

Related Summaries